TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05615441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia Nociception Index monitor
Description: Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard monitoring
Description: Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
Study: NCT05864014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Hetrombopag
Study: NCT06488846

Intervention type: OTHER
Intervention: INVITE-Home
Description: Curriculum to train Treatment Buddies, selected by the people with HIV, to administer LAI-ART at home with supervision of a Study Nurse.
Study: NCT05864014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag plus Placebo
Description: Hetrombopag plus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06488846

Intervention type: OTHER
Intervention: Clinic-Administered LAI-ART
Description: People with HIV who continue to receive LAI-ART in clinic

Intervention type: OTHER
Intervention: Oral ART
Description: Oral ART
Study: NCT05345509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept Tablet
Description: Donepezil Tablet once daily P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3003
Description: Donepezil Long-Acting Injection, once S.C Injection
Study: NCT05189197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib + R-CHOP
Description: Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year.
Study: NCT05859958

Intervention type: OTHER
Intervention: No Intervention
Description: Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups

Intervention type: OTHER
Intervention: No Intervention
Description: Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
Study: NCT04674163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample and Cerebrospinal fluid (CSF) collection.
Description: An additional blood sample (25 ml) and a cerebrospinal fluid (CSF) sample (2 ml) will be taken.
Study: NCT06196840

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX102 subretinal injection
Description: LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX102 subretinal injection
Description: LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept intravitreal injection
Description: Commercially available Active Comparator
Study: NCT04323501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Description: Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Usual care
Study: NCT05992779

Intervention type: OTHER
Intervention: Measuring the vocal audiometry of patients.
Description: Measuring vocal audiometry at 6 months, 1 year and annually until the last date of follow-up

Intervention type: OTHER
Intervention: Measuring data loging
Description: Measuring data loging at 6 months, 1 year and then annually until last date of follow-up
Study: NCT06034223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training using head mounted laser
Description: Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical therpay
Description: Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physical therpay
Description: Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
Study: NCT06353646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XH001
Description: mRNA neoantigen cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XH001
Description: mRNA neoantigen cancer vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection
Description: a type of immunotherapy that targets CTLA-4 protein on T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection
Description: a type of immunotherapy that targets CTLA-4 protein on T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: gemcitabine + capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: gemcitabine + capecitabine
Study: NCT06143956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally. ISA specific interventions will be listed in the ISA.
Study: NCT06572852

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06148519

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2WIN-S portable refractor
Description: All participants will be tested by 2WIN-S portable refractor without eye dilatation. If the 2WIN-S reports non-referral, participant will be tested visual acuity by optometrist. If the 2WIN-S reports referral, participant will be tested cycloplegic refraction by pediatric ophthalmologist, then tested by 2WIN-S again. The participant whose result is abnormal will be referred to the hospital for further management.
Study: NCT06217406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (ACYCLOVIR )
Description: Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline bags
Description: Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
Study: NCT03086850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of daily physical activity with a pedometer
Description: Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~* \<6000 steps/day: increase by 3000 steps/day~* 6000 - 10000 steps/day: reach 10000 steps/day~* \> 10000 steps/day: maintain or increase steps

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
Study: NCT05345509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3003
Description: Donepezil Long-Acting Injection, once S.C Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3003
Description: Donepezil Long-Acting Injection, once S.C Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3003
Description: Donepezil Long-Acting Injection, once IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3003
Description: Donepezil Long-Acting Injection, once IM Injection
Study: NCT06572852

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05037461

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose-high precision MR-guided radiotherapy
Description: MR-guided radiotherapy as described in the group information
Study: NCT06485089

Intervention type: DRUG
Intervention: tirzepatide
Description: Women taking tirzepatide as part of standard care in the Weight Managment Clinic
Study: NCT05370807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 40 MG Oral Tablet
Description: Patients take 2 regorafenib oral tablets of 40 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triplet therapy
Description: Regorafenib in combination with BRAF- / MEK- inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triplet therapy
Description: Regorafenib in combination with BRAF- / MEK- inhibitors
Study: NCT05470348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study: NCT06587464

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06432751

Intervention type: OTHER
Intervention: Post Operative Acute Kidney Injury
Description: Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file
Study: NCT06680869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Hydrochloride Injection
Description: The use of a modified treatment protocol by emergency medical services where the initial dose of amiodarone is given after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Protocol
Description: The use of a usual care treatment protocol by emergency medical services where the initial dose of amiodarone is given after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study.
Study: NCT05907538

Intervention type: OTHER
Intervention: Interoceptive accuracy measurement
Description: Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).

Intervention type: OTHER
Intervention: Interoceptive accuracy measurement
Description: Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).

Intervention type: OTHER
Intervention: Interoceptive accuracy measurement
Description: Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).

Intervention type: OTHER
Intervention: Interoceptive sensibility measurement
Description: Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)

Intervention type: OTHER
Intervention: Interoceptive sensibility measurement
Description: Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)

Intervention type: OTHER
Intervention: Interoceptive sensibility measurement
Description: Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)

Intervention type: OTHER
Intervention: Interoceptive awareness measurement
Description: Interoceptive awareness will be measures using a visual analogue scale (VAS)

Intervention type: OTHER
Intervention: Interoceptive awareness measurement
Description: Interoceptive awareness will be measures using a visual analogue scale (VAS)

Intervention type: OTHER
Intervention: Interoceptive awareness measurement
Description: Interoceptive awareness will be measures using a visual analogue scale (VAS)
Study: NCT04029155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung biopsy
Description: Transbronchial Needle Aspiration performed via a ultra thin bronchoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung biopsy
Description: Transbronchial Needle Aspiration performed via a ultra thin bronchoscope
Study: NCT06640335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-ingestion
Description: Subjects co-ingest both (300 g mashed potatoes) and (200 g baby round spinach supplemented with canola oil) in the same time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 min preload
Description: Subjects consume 200 g baby round spinach supplemented with canola oil first, then directly consume 300 g of mashed potatoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min preload
Description: Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 5 minutes, then consume 300 g of mashed potatoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 min preload
Description: Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 min preload
Description: Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 min preload
Description: Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 15 minutes, then consume 300 g of mashed potatoes.
Study: NCT04706403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication from a physician about the COVID-19 Vaccine
Description: Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication from a physician about the COVID-19 Vaccine
Description: Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication from a physician about the COVID-19 Vaccine
Description: Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication from a physician about the COVID-19 Vaccine
Description: Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication from a physician about the COVID-19 Vaccine
Description: Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
Study: NCT05788965

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: glucagon-like peptide 1 (GLP-1) receptor agonist
Study: NCT05389787

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is \~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is \~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
Study: NCT04964726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time fMRI dyadic neurofeedback
Description: Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
Study: NCT05457920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: continuous treatment
Description: The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulse therapy
Description: pulse therapy
Study: NCT04879719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ego-depletion
Description: The surgery video lasts for 9 minutes and participants are asked to suppress their emotions. After the intervention several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The surgery video lasts for 9 minutes and participants in the control group are asked to watch the surgery video without the need to suppress their emotions. Several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed after the 9 minute video sequence.
Study: NCT06625463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based cardiac rehabilitation
Description: 12 week home based cardiac rehabilitation include Physical exercise, dietary management, smoking cessation and stress management
Study: NCT05248308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene Microspheres
Description: Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain.